Advertisement
IBIO vs NUVB
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IBIO is a Buy and NUVB is a StrongBuy.
IBIO's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for IBIO turned positive on October 27, 2026. Looking at past instances where IBIO's MACD turned positive, the stock continued to rise in 35 of 38 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IBIO's RSI Indicator exited the oversold zone, 34 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +10.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBIO advanced for three days, in 189 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
IBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IBIO as a result. In 72 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for IBIO entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.575) is normal, around the industry mean (2.974). P/E Ratio (-2.397) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (1250.000) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. IBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
NUVB in upward trend: price may jump up because it broke its lower Bollinger Band on October 02, 2026
NUVB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 27 of 32 cases where NUVB's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NUVB's RSI Oscillator exited the oversold zone, 24 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 63 cases where NUVB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for NUVB just turned positive on October 21, 2026. Looking at past instances where NUVB's MACD turned positive, the stock continued to rise in 43 of 52 cases over the following month. The odds of a continued upward trend are 83%.
Following a +8.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where NUVB advanced for three days, in 205 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NUVB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for NUVB entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.293) is normal, around the industry mean (2.974). P/E Ratio (-10.341) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (11.765) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. NUVB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NUVB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
IBIO | NUVB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 54 | 6 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 69 Overvalued | 23 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 91 | 64 | |
P/E GROWTH RATING 1..100 | 10 | 18 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NUVB's Valuation (23) in the null industry is somewhat better than the same rating for IBIO (69) in the Biotechnology industry. This means that NUVB’s stock grew somewhat faster than IBIO’s over the last 12 months.
NUVB's Profit vs Risk Rating (100) in the null industry is in the same range as IBIO (100) in the Biotechnology industry. This means that NUVB’s stock grew similarly to IBIO’s over the last 12 months.
NUVB's SMR Rating (98) in the null industry is in the same range as IBIO (98) in the Biotechnology industry. This means that NUVB’s stock grew similarly to IBIO’s over the last 12 months.
NUVB's Price Growth Rating (64) in the null industry is in the same range as IBIO (91) in the Biotechnology industry. This means that NUVB’s stock grew similarly to IBIO’s over the last 12 months.
IBIO's P/E Growth Rating (10) in the Biotechnology industry is in the same range as NUVB (18) in the null industry. This means that IBIO’s stock grew similarly to NUVB’s over the last 12 months.
| IBIO | NUVB | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 85% | 2 days ago 75% |
| Stochastic ODDS (%) | 2 days ago 85% | 2 days ago 76% |
| Momentum ODDS (%) | 2 days ago 90% | N/A |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 83% |
| TrendWeek ODDS (%) | 2 days ago 89% | 2 days ago 85% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 86% |
| Advances ODDS (%) | 8 days ago 84% | 8 days ago 84% |
| Declines ODDS (%) | 3 days ago 89% | 3 days ago 86% |
| BollingerBands ODDS (%) | 2 days ago 85% | 2 days ago 84% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IBIO’s FA Score shows that 1 FA rating(s) are green while NUVB’s FA Score has 2 green FA rating(s).
- IBIO’s FA Score: 1 green, 4 red.
- NUVB’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IBIO’s TA Score shows that 5 TA indicator(s) are bullish while NUVB’s TA Score has 5 bullish TA indicator(s).
- IBIO’s TA Score: 5 bullish, 3 bearish.
- NUVB’s TA Score: 5 bullish, 2 bearish.
Price Growth
IBIO (@Biotechnology) experienced а -6.59% price change this week, while NUVB (@Biotechnology) price change was -4.61% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.06%. For the same industry, the average monthly price growth was -11.24%, and the average quarterly price growth was -13.36%.
Reported Earning Dates
IBIO is expected to report earnings on Nov 11, 2026.
NUVB is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (+2.06% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
IBIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, IBIO has been loosely correlated with WVE. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if IBIO jumps, then WVE could also see price increases.
| Ticker / NAME | Correlation To IBIO | 1D Price Change % | ||
|---|---|---|---|---|
| IBIO | 100% | +8.47% | ||
| WVE - IBIO | 47% Loosely correlated | +7.48% | ||
| REPL - IBIO | 38% Loosely correlated | +4.65% | ||
| GPCR - IBIO | 34% Loosely correlated | +2.13% | ||
| NUVB - IBIO | 34% Loosely correlated | +0.89% | ||
| ABCL - IBIO | 34% Loosely correlated | +6.21% | ||
More | ||||
NUVB and
Correlation & Price change
A.I.dvisor indicates that over the last year, NUVB has been loosely correlated with SVRA. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVB jumps, then SVRA could also see price increases.
| Ticker / NAME | Correlation To NUVB | 1D Price Change % | ||
|---|---|---|---|---|
| NUVB | 100% | +0.89% | ||
| SVRA - NUVB | 45% Loosely correlated | +7.52% | ||
| FDMT - NUVB | 41% Loosely correlated | +8.43% | ||
| VCYT - NUVB | 40% Loosely correlated | +4.32% | ||
| ANNX - NUVB | 39% Loosely correlated | +1.62% | ||
| RAPP - NUVB | 38% Loosely correlated | +8.72% | ||
More | ||||